2-(2-溴环戊烯-1-基)-4-氯-1-甲氧基苯 | 850864-61-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(2-溴环戊烯-1-基)-4-氯-1-甲氧基苯
• 英文名称: 2-(2-Bromocyclopent-1-en-1-yl)-4-chloro-1-methoxybenzene
• 英文别名: 2-(2-bromocyclopenten-1-yl)-4-chloro-1-methoxybenzene
• CAS: 850864-61-8
• 化学式: C₁₂H₁₂BrClO
• 分子量: 287.584
• InChiKey: FIMCMFXURWAQOA-UHFFFAOYSA-N

物化性质

• 沸点：
  368.1±42.0 °C(Predicted)
• 密度：
  1.493±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2-溴环戊烯-1-基)-4-氯-1-甲氧基苯 在 四(三苯基膦)钯 sodium hydroxide 、 sodium thiomethoxide 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 生成 3-{2-[5-chloro-2-(benzyloxy)phenyl]cyclopent-1-enyl}benzoic acid
  参考文献：
  名称：

  The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain

  摘要：

  The discovery of a series of selective EP1 receptor antagonists based on a 1,2-diaryleyclopentene template is described. After defining the structural requirements for EP1 potency and selectivity, heterocyclic rings were incorporated to reduce logD and improve in vitro pharmacokinetic properties. The 2,6-substituted pyridines and pyridazines gave an appropriate balance of potency, in vivo pharmacokinetic properties and a low potential for inhibiting a range of CYP450 enzymes. From this series, GW848687X was shown to have an excellent profile in models of inflammatory pain and was selected as a development candidate. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.041
• 作为产物：
  描述：

  2-溴-1-环戊烯硼酸 、 4-氯-2-碘苯甲醚, 在 四(三苯基膦)钯 作用下， 以 乙醇 、 甲苯 为溶剂， 生成 2-(2-溴环戊烯-1-基)-4-氯-1-甲氧基苯
  参考文献：
  名称：

  The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain

  摘要：

  The discovery of a series of selective EP1 receptor antagonists based on a 1,2-diaryleyclopentene template is described. After defining the structural requirements for EP1 potency and selectivity, heterocyclic rings were incorporated to reduce logD and improve in vitro pharmacokinetic properties. The 2,6-substituted pyridines and pyridazines gave an appropriate balance of potency, in vivo pharmacokinetic properties and a low potential for inhibiting a range of CYP450 enzymes. From this series, GW848687X was shown to have an excellent profile in models of inflammatory pain and was selected as a development candidate. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.041

文献信息

• [EN] CYCLOPENTENE COMPOUNDS<br/>[FR] COMPOSES DE CYCLOPENTENE
  申请人：GLAXO GROUP LTD

  公开号：WO2005037793A1

  公开（公告）日：2005-04-28

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, B, Z, R1, R2a, R2b, R8, R9, and Rx are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  式（I）的化合物或其药用可接受的衍生物：其中A、B、Z、R1、R2a、R2b、R8、R9和Rx如规范中定义的那样，一种制备这种化合物的方法，包含这种化合物的药物组合物以及这种化合物在医学中的用途。
• Cyclopentene compounds
  申请人：Giblin Gerard Martin Paul

  公开号：US20090227591A1

  公开（公告）日：2009-09-10

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, B, Z, R 1 , R 2a , R 2b , R 8 , R 9 , and R x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  化合物的式子（I）或其药学上可接受的衍生物： 其中A、B、Z、R1、R2a、R2b、R8、R9和Rx如规范中所定义，制备这种化合物的工艺，包含这种化合物的制药组合物以及这种化合物在医学上的用途。
• CYCLOPENTENE COMPOUNDS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1670763A1

  公开（公告）日：2006-06-21
• The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain
  作者：Gerard M.P. Giblin、Rino A. Bit、Susan H. Brown、Hélène M. Chaignot、Anita Chowdhury、Iain P. Chessell、Nicholas M. Clayton、Tanya Coleman、Adrian Hall、Beverley Hammond、David N. Hurst、Anton D. Michel、Alan Naylor、Riccardo Novelli、Tiziana Scoccitti、David Spalding、Sac P. Tang、Alex W. Wilson、Rich Wilson

  DOI：10.1016/j.bmcl.2006.10.041

  日期：2007.1

  The discovery of a series of selective EP1 receptor antagonists based on a 1,2-diaryleyclopentene template is described. After defining the structural requirements for EP1 potency and selectivity, heterocyclic rings were incorporated to reduce logD and improve in vitro pharmacokinetic properties. The 2,6-substituted pyridines and pyridazines gave an appropriate balance of potency, in vivo pharmacokinetic properties and a low potential for inhibiting a range of CYP450 enzymes. From this series, GW848687X was shown to have an excellent profile in models of inflammatory pain and was selected as a development candidate. (c) 2006 Elsevier Ltd. All rights reserved.